UTIBRON NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Oct 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UTIBRON NEOHALER is a combination inhalation powder approved by the FDA in 2015 for chronic obstructive pulmonary disease (COPD) maintenance therapy. The specific active ingredients and mechanism of action are not disclosed in available data, but the product is formulated as a dry powder for oral inhalation. It represents Novartis's investment in respiratory disease management via innovative delivery technology.
LOE Approaching2.0 years to LOE
With LOE approaching by October 2028 and only 2 years of exclusivity remaining, the brand team is likely in transition or consolidation mode, with smaller team size and focus on market defense rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on UTIBRON NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.